## Vincent Fradet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4652454/publications.pdf

Version: 2024-02-01

279798 265206 1,842 79 23 42 citations h-index g-index papers 81 81 81 2732 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy. Clinical Nutrition ESPEN, 2022, 47, 221-226.	1.2	2
2	Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 164, 102215.	2.2	13
3	A multiâ€institutional randomized controlled trial comparing firstâ€generation transrectal highâ€resolution microâ€ultrasound with conventional frequency transrectal ultrasound for prostate biopsy. BJUI Compass, 2021, 2, 126-133.	1.3	17
4	18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association Journal, 2021, 15, 301-307.	0.6	5
5	Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findings. BMC Medical Genomics, 2021, 14, 167.	1.5	10
6	Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Current Developments in Nutrition, 2021, 5, nzab106.	0.3	2
7	A glycan-based plasmonic sensor for prostate cancer diagnosis. Analyst, The, 2021, 146, 6852-6860.	3.5	2
8	Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity. Molecular Cancer Research, 2021, 19, 516-527.	3.4	10
9	Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. European Urology Oncology, 2020, 3, 298-305.	5.4	15
10	Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study. Canadian Urological Association Journal, 2020, 15, 181-186.	0.6	13
11	Assembling a network to promote translational bladder cancer research in Canada. Canadian Urological Association Journal, 2020, 14, E475-E481.	0.6	1
12	Omegaâ€3 fatty acids decrease prostate cancer progression associated with an antiâ€tumor immune response in eugonadal and castrated mice. Prostate, 2019, 79, 9-20.	2.3	28
13	Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level. Nutrients, 2019, 11, 1616.	4.1	13
14	Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?. Clinical Genitourinary Cancer, 2019, 17, e1122-e1128.	1.9	9
15	The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study. European Urology Supplements, 2019, 18, e144.	0.1	3
16	Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 300.e9-300.e15.	1.6	21
17	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8–10 Prostate Cancers Identifies Very High–risk Patients for Early Recurrence and Resistance to Castration. European Urology Focus, 2019. 5. 998-1006.	3.1	25
18	Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with lowâ€risk prostate cancer receiving 5αâ€reductase inhibitors. BJU International, 2018, 121, 399-404.	2.5	10

#	Article	IF	CITATIONS
19	Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase Ilb, randomized, double-blind, placebo-controlled trial. BMC Cancer, 2018, 18, 64.	2.6	15
20	Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA+P) Journal of Clinical Oncology, 2018, 36, 196-196.	1.6	3
21	Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus, 2017, 3, 639-642.	3.1	15
22	Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study. Nutrition and Cancer, 2017, 69, 1196-1204.	2.0	10
23	MP14-04 CARDIOVASCULAR DISEASE CHARACTERISTICS OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS: FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN MEN WITH PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	2
24	Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population. Canadian Urological Association Journal, 2017, 11, 404-10.	0.6	10
25	Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review. Canadian Urological Association Journal, 2017, 11, 419-24.	0.6	5
26	Urology residents on call: Investigating the workload and relevance of calls. Canadian Urological Association Journal, 2017, 12, E71-5.	0.6	3
27	Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC) Journal of Clinical Oncology, 2017, 35, 238-238.	1.6	0
28	Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy Journal of Clinical Oncology, 2017, 35, e590-e590.	1.6	0
29	Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients. European Journal of Cardio-thoracic Surgery, 2016, 50, 317-321.	1.4	21
30	Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC). International Journal of Radiation Oncology Biology Physics, 2016, 96, E531-E532.	0.8	1
31	Assessing Cancer Risk on Novel 29 MHz Micro-Ultrasound Images of the Prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification. Journal of Urology, 2016, 196, 562-569.	0.4	104
32	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction. Cancer Prevention Research, 2016, 9, 189-195.	1.5	11
33	The RADICAL-PC trial Journal of Clinical Oncology, 2016, 34, 178-178.	1.6	3
34	MP1-03 VALIDATED URINE-BASED MULTIGENE SIGNATURE FOR DETECTION OF AGGRESSIVE PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
35	Malignant mesothelioma of the <i>tunica vaginalis</i> testis: comprehensive review of literature and case report. Journal of Clinical Urology, 2015, 8, 147-152.	0.1	1
36	Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagnostic Pathology, 2015, 10, 67.	2.0	23

#	Article	IF	CITATIONS
37	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging, 2015, 15, 2.	2.8	47
38	Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer. JAMA Oncology, 2015, 1, 1261.	7.1	94
39	Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. European Journal of Clinical Nutrition, 2015, 69, 1004-1008.	2.9	11
40	Burden of illness of bone metastases in prostate cancer patients in Quà ©bec, Canada: A population-based analysis. Canadian Urological Association Journal, 2015, 9, 307.	0.6	12
41	IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness. Research and Reports in Urology, 2014, 6, 27.	1.0	26
42	Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance. Cancer Prevention Research, 2014, 7, 766-776.	1.5	28
43	MP79-11 IMPACT OF KI67 LABELING INDEX ON PROGRESSION AND DEATH OF PROSTATE CANCER POST-PROSTATECTOMY: COMPARISON OF VISUAL AND AUTOMATED SCORING. Journal of Urology, 2014, 191, .	0.4	0
44	Diagnostic Performance of Ultrasound for Macroscopic Hematuria in the Era of Multidetector Computed Tomography Urography. Canadian Association of Radiologists Journal, 2014, 65, 253-259.	2.0	11
45	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors Urologic Oncology: Seminars and Original Investigations, 2014, 32, 839-845.	1.6	44
46	The Impact of Solitary and Multiple Positive Surgical Margins on Hard Clinical End Points in 1712 Adjuvant Treatment–Naive pT2–4 NO Radical Prostatectomy Patients. European Urology, 2013, 64, 19-25.	1.9	82
47	241 DETERMINATION OF THE ACCURACY OF FDG-PET/CT IN THE PRIMARY STAGING OF BIOLOGICAL HIGH RISK PROSTATE CANCERS BEFORE LOCAL THERAPIES: INCREASED UPTAKE ASSOCIATED WITH HIGHLY AGGRESSIVE TUMORS. Journal of Urology, 2013, 189, .	0.4	0
48	Intermittent Versus Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 87, S156-S157.	0.8	0
49	1297 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR PREOPERATIVE STAGING AND POSTOPERATIVE FOLLOW-UP OF UROTHELIAL CARCINOMA. Journal of Urology, 2013, 189, .	0.4	0
50	2199 GLUT-1, GLUT-12 AND HK2 PROTEIN EXPRESSION IN PROSTATIC ADENOCARNINOMA: CLINICAL CORRELATION WITH INTRAPROSTATIC 18F-FDG-POSITRON EMISSION TOMOGRAPHY (FDG-PET) UPTAKE. Journal of Urology, 2013, 189, .	0.4	0
51	High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Human Pathology, 2013, 44, 1630-1637.	2.0	30
52	Reply from Authors re: Martin Spahn, Steven Joniau. Positive Surgical Margin at Radical Prostatectomy: Futile or Surgeon-dependent Predictor of Prostate Cancer Death? Eur Urol 2013;64:26–8. European Urology, 2013, 64, 28-29.	1.9	2
53	Green tea for ovarian cancer prevention and treatment: A systematic review of the in vitro, in vivo and epidemiological studies. Gynecologic Oncology, 2012, 126, 491-498.	1.4	36
54	Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer. Canadian Urological Association Journal, 2012, 1, 269-72.	0.6	14

#	Article	IF	Citations
55	The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. European Urology, 2012, 62, 88-96.	1.9	33
56	Poor Agreement of Prostate Specific Antigen Doubling Times Calculated Using Ultrasensitive Versus Standard Prostate Specific Antigen Values: Important Impact on Risk Assessment. Journal of Urology, 2011, 186, 2228-2232.	0.4	8
57	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. European Urology, 2011, 60, 1226-1234.	1.9	41
58	Dietary Omega-3 Fatty Acids, Genetic Variation and Risk of Breast and Prostate Cancers. World Review of Nutrition and Dietetics, 2011, 102, 156-171.	0.3	6
59	Urologist Density and County-Level Urologic Cancer Mortality. Journal of Clinical Oncology, 2010, 28, 2499-2504.	1.6	78
60	Prostate Cancer Managed with Active Surveillance: Role of Anatomic MR Imaging and MR Spectroscopic Imaging. Radiology, 2010, 256, 176-183.	7.3	116
61	Dietary Omega-3 Fatty Acids, <i>Cyclooxygenase-2</i> Genetic Variation, and Aggressive Prostate Cancer Risk. Clinical Cancer Research, 2009, 15, 2559-2566.	7.0	126
62	Penile Sonographic and Clinical Characteristics in Men with Peyronie's Disease. Journal of Sexual Medicine, 2009, 6, 2858-2867.	0.6	29
63	Prospective Assessment of Malnutrition in Urologic Patients. Urology, 2009, 73, 1072-1076.	1.0	81
64	ω–3 Fatty Acids, Genetic Variants in COX-2 and Prostate Cancer. Journal of Nutrigenetics and Nutrigenomics, 2009, 2, 149-158.	1.3	32
65	RISK OF MALNUTRITION IN UROLOGICAL PATIENTS. Journal of Urology, 2009, 181, 8-8.	0.4	2
66	Is the Complication Rate of Radical Cystectomy Predictive of the Complication Rate of Other Urological Procedures?. Journal of Urology, 2009, 181, 1054-1060.	0.4	2
67	PATHOLOGIC OUTCOMES IN MEN MEETING CRITERIA FOR ACTIVE SURVEILLANCE OF PROSTATE CANCER. Journal of Urology, 2009, 181, 60-60.	0.4	2
68	Pathological Outcomes of Candidates for Active Surveillance of Prostate Cancer. Journal of Urology, 2009, 181, 1628-1634.	0.4	162
69	REFLEX IMMUNOCYT TESTING FOR DIAGNOSIS OF BLADDER CANCER IN PATIENTS WITH ATYPICAL URINE CYTOLOGY. Journal of Urology, 2009, 181, 419-419.	0.4	0
70	Geographic Distribution of Urologists Throughout the United States Using a County Level Approach. Journal of Urology, 2009, 181, 760-766.	0.4	79
71	THE RELATIONSHIP BETWEEN LOCAL UROLOGIST DENSITY AND PROSTATE, BLADDER, AND KIDNEY CANCER MORTALITY. Journal of Urology, 2009, 181, 163-163.	0.4	1
72	INTAKE OF A HEALTHY DIET PATTERN AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS DIAGNOSED WITH PROSTATE CANCER. Journal of Urology, 2008, 179, 608-609.	0.4	0

#	Article	IF	CITATIONS
73	DIETARY LONG-CHAIN OMEGA-3 FATTY ACIDS, COX2 GENE POLYMORPHISM, AND AGGRESSIVE PROSTATE CANCER. Journal of Urology, 2008, 179, 149-149.	0.4	1
74	Re: Results from three municipal hospitals regarding radical cystectomy on elderly patients. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2008, 34, 97-98.	1.5	0
75	Statins and superficial bladder cancer evolution after diagnosis: A population-based study. Journal of Clinical Oncology, 2008, 26, 22047-22047.	1.6	0
76	A DELAY IN RADICAL CYSTECTOMY OF >3 MONTHS IS NOT ASSOCIATED WITH A WORSE CLINICAL OUTCOME. BJU International, 2007, 101, 257-258.	2.5	0
77	The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2006, 49, 273-279.	1.9	45
78	Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer. Clinical Cancer Research, 2004, 10, 8460-8464.	7.0	130
79	Total cholesterol correlates with cyclosporine C2 levels in kidney transplant recipients under maintenance immunosuppression. Transplantation Proceedings, 2004, 36, S448-S450.	0.6	4